Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jan;5(1):35-41.
doi: 10.1007/s11882-005-0052-6.

CD25+ T cells and regulation of allergen-induced responses

Affiliations
Review

CD25+ T cells and regulation of allergen-induced responses

Marina Ostroukhova et al. Curr Allergy Asthma Rep. 2005 Jan.

Abstract

CD4 T helper 2 (Th2) cells, with the characteristic interleukin (IL)-4, IL-5, and IL-13 cytokine secretion profile, play an important role in the initiation and perpetuation of allergic airways disease. It is clear from recent studies that CD4+ T cells with distinct cytokine-producing abilities have regulatory functions that limit allergic inflammation. Studies of allergic airway inflammation in mice have identified different types of T regulatory cells (Tregs) that control the disease phenotype. The cytokines associated with the Treg phenotype in mice include both soluble and cell membrane-bound transforming growth factor (TGF)-beta and IL-10. Both contact-dependent mechanisms involving membrane-bound TGF-beta and contact-independent mechanisms involving soluble TGF-beta and IL-10 have been invoked to describe the function of these Tregs. In humans, studies of milk allergy show an association between circulating CD4+CD25+ Tregs and tolerance to the causative allergen, beta-lactoglobulin. The identification of Tregs as suppressors of allergic disease may promote the development of new therapeutic strategies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Science. 1969 Nov 7;166(3906):753-5 - PubMed
    1. J Exp Med. 1998 Mar 2;187(5):721-31 - PubMed
    1. Nat Immunol. 2001 Aug;2(8):725-31 - PubMed
    1. Annu Rev Immunol. 2004;22:789-815 - PubMed
    1. J Clin Invest. 2000 Dec;106(12):R75-81 - PubMed

MeSH terms